Page 238 - 2022_01-Haematologica-web

C.Rossi et al.
Funding
This work was supported in part by institutional grants from INSERM, Université Paul Sabatier and CNRS, Institut Claudius Regaud CLCC (contract R20027BB, CIEL) the Laboratoire
d'Excellence Toulouse Cancer (TOUCAN) (contract ANR11- LABX) and the Programme Hospitalo-Universitaire en Cancérologie CAPTOR (contract ANR11-PHUC0001). CR obtained a grant from ITMO Cancer Plan Cancer 2014-2019.
References
1. Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analy- sis of French and US cohorts. J Clin Oncol. 2019;37(2):144-152.
2. Dada R. Diagnosis and management of fol- licular lymphoma: a comprehensive review. Eur J Haematol 2019;103(3):152-163.
3. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after ritux- imab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an Analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516-2522.
4. Bodet-Milin C, Kraeber-Bodéré F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histologi- cal transformation of indolent lymphoma. Haematologica. 2008;93(3):471-472.
5. Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemother- apy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1530-1542.
6. Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multi- center studies. J Clin Oncol. 2016;34(30): 3618-3626.
7. Bailly C, Carlier T, Berriolo-Riedinger A, et al. Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. Haematologica. 2020;105 (1):e33-e36.
8. Strati P, Ahmed MAA, Fowler N, et al. Pre- treatment maximum standardized uptake value predicts outcome after frontline thera- py in patients with advanced stage follicular lymphoma. Haematologica. 2020;105(7): 1907-1913.
9. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351 (21):2159-2169.
10. Laurent C, Charmpi K, Gravelle P, et al. Several immune escape patterns in non- Hodgkin’s lymphomas. Oncoimmunology. 2015;4(8):e1026530.
11. Huet S, Tesson B, Jais J-P, et al. A gene- expression profiling score for prediction of outcome in patients with follicular lym- phoma: a retrospective training and valida- tion analysis in three international cohorts. Lancet Oncol. 2018;19(4):549-561.
12. Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prog- nostication for patients receiving first-line immunochemotherapy for follicular lym- phoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111-1122.
13. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
14. Kanoun S, Tal I, Berriolo-Riedinger A, et al. Influence of software tool and methodolog- ical aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to pre- dict survival in Hodgkin lymphoma. PLoS One. 2015;10(10):e0140830.
15. Laurent C, Guérin M, Frenois F-X, et al. Whole-slide imaging is a robust alternative to traditional fluorescent microscopy for flu- orescence in situ hybridization imaging using break-apart DNA probes. Hum Pathol. 2013;44(8):1544-1555.
16.Péricart S, Tosolini M, Gravelle P, et al. Profiling immune escape in Hodgkin’s and diffuse large B-cell lymphomas using the transcriptome and immunostaining. Cancers. 2018;10(11):415.
17.Evrard SM, Péricart S, Grand D, et al. Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Haematologica. 2019;104 (4):e154-e157.
18. Vendrell JA, Grand D, Rouquette I, et al. High-throughput detection of clinically tar- getable alterations using next-generation sequencing. Oncotarget. 2017;8(25):40345- 40358.
19. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9(1):191-192.
20. Therneau T. 2020. A package for survival analysis in R. R package version 3.2-3 https://CRAN.R-project.org/package=sur- vival.
21. Terry M. Therneau, Patricia M. Grambsch. Modeling survival data: extending the Cox ModelA package for survival analysis in R. R package version 3.2-3, at https://CRAN.R- project.org/package=survival. New York. Springer. 2000.
22. Benjamini, Y, Hochberg, Y. Controlling the false discovery rate - a practical and power- ful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57:289-300.
23. Reshef DN, Reshef YA, Finucane HK, et al. Detecting novel associations in large data sets. Science. 2011;334(6062):1518-1524.
24. Tosolini M, Algans C, Pont F, Ycart B, Fournié J-J. Large-scale microarray profiling reveals four stages of immune escape in non- Hodgkin lymphomas. Oncoimmunology. 2016;5(7):e1188246.
25. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, ran- domised controlled trial. Lancet. 2011;377(9759):42-51.
26. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25-29.
27. Fabregat A, Sidiropoulos K, Garapati P, et al.
The Reactome pathway Knowledgebase.
Nucleic Acids Res. 2016;44(D1):D481-487. 28. Rummel MJ, Al-Batran SE, Kim S-Z, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non- Hodgkin’s lymphoma. J Clin Oncol.
2005;23(15):3383-3389.
29. Batlevi CL, Sha F, Alperovich A, et al.
Positron-emission tomography-based stag- ing reduces the prognostic impact of early disease progression in patients with follicu- lar lymphoma. Eur J Cancer. 2020;126:78-90.
30. Alobthani G, Romanov V, Isohashi K, et al. Value of 18F-FDG PET/CT in discrimination between indolent and aggressive non- Hodgkin’s lymphoma: A study of 328 patients. Hell J Nucl Med. 2018;21(1):7-14.
31. Schöder H, Noy A, Gönen M, et al. Intensity of 18 Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non- Hodgkin’s lymphoma. J Clin Oncol. 2005;23 (21):4643-4651.
32. Xerri L, Huet S, Venstrom JM, et al. Rituximab treatment circumvents the prog- nostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. Hum Pathol. 2017;64:128-136.
33. Bachy E, Seymour JF, Feugier P, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA Study. J Clin Oncol. 2019;37 (31):2815-2824.
34. Barrington SF, Trotman J, Sahin D, et al. Baseline PET-derived metabolic tumor vol- ume metrics did not predict outcomes in fol- licular lymphoma patients treated with first- line immunochemotherapy and antibody maintenance in the phase III GALLIUM study. Blood. 2018;132(Suppl 1):S2882-2882.
35. Falchi L, Ferrajoli A, Jacobs I, Nava-Parada P. An evidence-based review of anti-CD20 antibody-containing regimens for the treat- ment of patients with relapsed or refractory chronic lymphocytic leukemia, diffuse large B-cell lymphoma, or follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18 (8):508-518.
36.Rushton CK, Arthur SE, Alcaide M, et al. Genetic and evolutionary patterns of treat- ment resistance in relapsed B-cell lym- phoma. Blood Adv. 2020;4(13):2886-2898.
37.Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk models predict early pro- gression of follicular lymphoma after first- line immunochemotherapy. Blood. 2016;128(8):1112-1120.
38.
Pyrzynska B, Dwojak M, Zerrouqi A, et al. FOXO1 promotes resistance of non- Hodgkin lymphomas to anti-CD20-based therapy. Oncoimmunology. 2018;7(5): e1423183.
39. Araf S, Wang J, Korfi K, et al. Genomic pro- filing reveals spatial intra-tumor heterogene- ity in follicular lymphoma. Leukemia. 2018;32(5):1261-1265.
230
haematologica | 2022; 107(1)